Gender Diversity In Pharma: Caught Between Desire And Reality

Charting The Executive Gender Mix Across 384 Companies

Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

Group
talent does not reside solely within the confines of one gender, color or ethnic background • Source: Shutterstock

Pharma as an industry suffers from cerebral dysmorphia: the structure of its head does not always match its body. The industry is struggling to align its executive management layer with the diversity in its workforce. There are short-term, symptomatic fixes for the condition but curative therapy is a protracted process that, at current rates, will take until 2050 to complete.

Beth Crowley is now senior vice president and chief product development officer at Celldex Therapeutics Inc., a clinical-stage antibody...

More from Leadership

More from In Vivo